Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fortress Biotech Inc (FBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 235,041
  • Shares Outstanding, K 50,330
  • Annual Sales, $ 16,480 K
  • Annual Income, $ -55,100 K
  • 36-Month Beta 1.16
  • Price/Sales 14.51
  • Price/Cash Flow 0.00
  • Price/Book 1.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.35 +7.36%
on 07/13/17
5.05 -7.52%
on 06/27/17
-0.17 (-3.51%)
since 06/20/17
3-Month
3.13 +49.20%
on 04/24/17
5.05 -7.52%
on 06/27/17
+1.41 (+43.25%)
since 04/20/17
52-Week
1.88 +148.40%
on 12/19/16
5.05 -7.52%
on 06/27/17
+1.74 (+59.39%)
since 07/20/16

Most Recent Stories

More News
Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences' CAEL-101

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that...

FBIO : 4.67 (-1.68%)
Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, announced that Lucy...

FBIO : 4.67 (-1.68%)
ATXI : 7.34 (+0.96%)
Avenue Therapeutics Completes Initial Public Offering

Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today that it has completed its initial public offering of 6,325,000 shares of common stock,...

FBIO : 4.67 (-1.68%)
NHLD : 2.85 (+1.42%)
ATXI : 7.34 (+0.96%)
Fortress Biotech (FBIO) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Fortress Biotech Inc (FBIO).

FBIO : 4.67 (-1.68%)
Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock

Avenue Therapeutics, Inc. ("Avenue"), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at an initial public...

FBIO : 4.67 (-1.68%)
NHLD : 2.85 (+1.42%)
ATXI : 7.34 (+0.96%)
Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company focused on the acquisition, development and commercialization of novel, non-chemotherapy, immune-enhanced...

FBIO : 4.67 (-1.68%)
CKPT : 7.67 (-14.78%)
Fortress Biotech to Present at the 2017 BIO International Convention

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that...

FBIO : 4.67 (-1.68%)
Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that...

FBIO : 4.67 (-1.68%)
Checkpoint Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Checkpoint Therapeutics, Inc. ("Checkpoint") (OTCQX:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present...

FBIO : 4.67 (-1.68%)
CKPT : 7.67 (-14.78%)
Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session

Fortress Biotech, Inc. (FBIO) shares rose over 5% in the last trading session.

ACIU : 8.02 (-1.23%)
FBIO : 4.67 (-1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Support & Resistance

2nd Resistance Point 5.02
1st Resistance Point 4.85
Last Price 4.67
1st Support Level 4.58
2nd Support Level 4.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.